split-banner-image

HOW BLOODYWORK IS USED IN CANCER CARE (LIQUID BIOPSY)

A liquid biopsy is a simple and non-invasive alternative to surgical biopsies, which enables doctors to discover a range of information about a tumour through a simple blood sample. Professor Rik Thompson discusses how liquid biopsy relates to breast cancer treatment and why it’s important in metastatic breast cancer.

What Is Liquid Biopsy?

A liquid biopsy is a simple and non-invasive alternative to surgical biopsies, which enables doctors to discover a range of information about a tumour through a simple blood sample.

This includes searching for cancer cells from a tumour that are circulating in the blood or for pieces of DNA from tumour cells in the blood.

It’s a research focus for Professor Rik Thompson, who is the Associate Director and a Professor of Breast Cancer Research at the Institute of Health and Biomedical Innovation and School of Biomedical Science at Queensland’s University of Technology.

Professor Thompson said blood work is an important part of treating the disease.

“Breast cancers use the blood system to escape and move around.”

“It uses the lymphatics as well, and there is an interchange between the blood and the lymphatics.”

“In women with a higher amount of breast cancer burden, more of their breast cancer cells find their way into the blood” he said.

“Over the years we’ve been able to develop techniques to find those needles in the haystack, to find those very small numbers of breast cancer cells in the blood and increasingly to look for cancer DNA in the blood.”

He said liquid biopsies are a window into how breast cancer can spread and metastasise.

“You can get an idea of what’s going on all around the body by having a look in the blood.”

“It’s very convenient, but it’s difficult and technically very challenging because you might have nearly a billion leucocytes in 10mls of blood and you might only have three of four breast cancer cells.”

“But one breast cancer cell amongst all those leucocytes has proven prognostic value.”

Listen to the podcast

Professor Rik Thompson discusses how liquid biopsy relates to breast cancer treatment and why it’s important in metastatic breast cancer.

How Liquid Biopsy Could Be Used In Breast Cancer Treatments

Professor Thompson said it’s hoped liquid biopsy will be used in the future to tailor breast cancer treatments and therapies.

“There are many studies with these initial technologies called the cell search technology, that continue to reinforce the prognostic value (of liquid biopsy) and the fact that if you’ve got more cells in the blood you have a higher risk of relapse.”

Professor Thompson said tumour DNA is becoming increasingly important in this area of study.

“The tumour DNA is becoming very important in a couple of ways. One is that it’s easier to see, rather than looking for one or two cells in 10mls of blood, you’re looking for probably thousands of copies of DNA.”

“It’s a little bit of an easier target.”

“So, those thousands of copies are hidden amongst billions of copies of DNA of normal cells that are circulating in the blood etc and are coming apart.”

He said researchers are getting better at being able to predict and measure DNA changes occurring in a tumour. He said this has implications for new treatment types like Immunotherapy, which has found success in other cancer types such as lung cancer and melanoma.

Research into immunotherapy for breast cancer is continuing.

“Triple negative breast cancer is more amenable to immunotherapy and there’s some terrific trials going on” said Professor Thompson.

“Tumour mutational burden is a key issue in how well immunotherapy can work and so monitoring the mutational state, the DNA level in the blood, is going to have some great benefits in immunotherapy.”

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Professor Rik Thompson

Professor Rik Thompson is the Associate Director and a Professor of Breast Cancer Research at the Institute of Health and Biomedical Innovation and School of Biomedical Science at Queensland’s University of Technology.

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

MENTAL HEALTH, BODY IMAGE & BREAST CANCER

How kind were you to yourself during and after your breast cancer treatment? Two women who have experienced a breast cancer diagnosis, Leslie Gilham and Leonie Young, speak about their experiences with mental health, body image and breast cancer.

The Impact A Diagnosis Has On Your Self-Esteem

Going through a breast cancer diagnosis can have a devastating impact on your physical health and your mental health.

Your body can go through many changes during treatment which can be hard to adjust to.

This can include the impact of chemotherapy or other treatments, or adjusting to your body with a mastectomy, bilateral mastectomy, lumpectomy or a reconstruction.

So how kind were you to yourself during and after your treatment?

The current Chair of Breast Cancer Trials Consumer Advisory Panel Leslie Gilham and the former Chair Leonie Young, both experienced changes to their mental health and body image throughout their treatment.

Leonie Young said she had to adjust to the changes to her body after breast cancer surgery.

“I had a mastectomy, so that was very obvious. But it’s no less important for women who have a lumpectomy, but it’s just a little more obvious when you have a mastectomy.”

She said even those who have undergone a reconstruction are left with scaring.

“It’s one of the biggest issues that women have to face going through this sort of surgery.”

“So, then it raises a whole array issues around sexuality and partnerships and marriages can struggle at this time because people don’t feel like they’re good enough.”

Leslie Gilham said it can be hard to adjust to the permanent reminder of your disease.

“For almost all women and men who’ve had a diagnosis, there’s a constant reminder every time you look at your own self-image, whether that’s because you’ve had a mastectomy, a lumpectomy or none at all.”

“You might have had radiation therapy, but you’ll still have some sort of marking or you’ll have tattoos, to remind you of the radiation, even down to chemotherapy, hair loss and that sort of thing” she said.

Listen to the Podcast

Consumer Advisor Panel Chair Leslie Gilham, and former Chair Leonie Young discuss the impact their breast cancer diagnosis has on their self esteem, body image and mental health.

She said de-escalation trials being conducted by Breast Cancer Trials, such as EXPERT and POSNOC, could help to lessen these impacts.
 
“Some of these issues could be alleviated a little bit by clinical trials.”
 
“For example, some of the treatments might cause lymphedema, which creates a whole different range of body issues as well.”

The Impact A Good Support System Can Have

Leslie said she felt very supported while undergoing treatment, thanks to her clinical trial team.

“I tended to have a whole group of people supporting me, not only my family and friends but also a whole team at the clinic.”

“I guess because I was on that trial, I had to attend the clinic more often, so I had that support around my well being, probably more than those people who weren’t on trials.”

“So, for me personally, I can say I had a lot of support for my mental health.”

Leonie said others receive less support.

“I’m a little different to Leslie because I wasn’t on a trial and I was diagnosed a long time ago and everything has certainly changed in that area and there’s a lot more support around these days.”

She said there is still gaps in the system, with some in regional areas missing out on support.

“For some women, depending on where they live, that support is not there and it’s really important for them to access it somehow.”

“I come from Brisbane and there’s a lot of good support around there but there’s some people who live in rural and regional areas who feel very isolated” she said.

“There are ways, thankfully with modern technology, that people can keep connected but that still keeps them isolated in some ways. So, there are still some people struggling in that area.”

Both women agreed that finding a group of people who have undergone a similar experience will help to support those undergoing treatment.

“If you’ve got a group of friends who all have got something similar going on, you don’t have to explain yourself around it. People get it. And you start to feel good about yourself after a while” said Leonie.

Leslie agreed.

“The more that you can surround yourself with people that have been through the same situation as yourself the better, because you don’t have to explain yourself, they get what you’re going through.”

“It’s actually interesting, you might raise something that is happening, or something that is concerning you and someone else will go ‘oh, that happened to me’.”

“So, it puts you at ease” she said.

“Because quite often you’ll find that if you speak to someone who hasn’t been through a diagnosis or someone who hasn’t got the medical background to deal with your concerns, then all you’re going to do is make those concerns worse because they’ll start to create the anxiety that you don’t necessarily need at that time.”

Practical Ways To Help Boost Self-Esteem

Leonie also suggested other practical ways to lift the self esteem of those undergoing treatment, such a breast forms and getting fitted for nice lingerie.

“Breast care nurses are really vital in steering people in the right direction to know where to go and where to find out some of those things.”

“A lot of people don’t know that those things are available for them and they struggle and feel they have to wear something that’s not very attractive at all. I guess it’s getting into the right information sources.”

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Leslie Gilham

Leslie Gilham is the Chair of the Breast Cancer Trials Consumer Advisory Panel
profile image

Leonie Young

Former Chair of the Breast Cancer Trials Consumer Advisory Panel

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

HOW REAL BREAST CANCER EXPERIENCES INFLUENCE TRIALS

Breast Cancer Trials was the first clinical trials group to invite people with a lived experience with cancer to comment and guide the planning and conduct of clinical trials research. These women make up our Consumer Advisory Panel. Former chair of the panel, Leonie Young, discusses the importance of this perspective in the clinical trials research process.

The Importance Of The Patient Experience

For those signing on to participate in a clinical trial, it can be reassuring to know that women who have a history of breast cancer have been involved in the planning of any new research.

For Breast Cancer Trials, this involves consulting with our Consumer Advisory Panel or CAP.

CAP is made up of women who have received a breast cancer diagnosis, and some have participated in a clinical trial.

Leonie Young is the former chair of Breast Cancer Trials Consumer Advisory Panel.

She said CAP is involved with Breast Cancer Trials research from concept development right through to patient care.

“Anybody considering a trial, especially if it’s badged with Breast Cancer Trials, should have a certain degree of confidence that people who’ve had that lived experience, who have been there done that, have actually looked at it and given their feedback on it.”

Listen to the podcast

Former chair of the Breast Cancer Trials Consumer Advisory Panel, Leonie Young, discusses the importance of the patient perspective in the clinical trials research process.

The Benefits Of Participating In A Clinical Trial

Ms Young said there are many common misconceptions regarding clinical trials.

“Nobody is disadvantaged on a clinical trial.”

“If you’re not on the treatment arm, you will still receive the golden standard treatment that everybody will receive if they’re not on a trial and when you think about it, if you go back a number of years, those drugs and those treatments were determined through the clinical trials research process” she said.

“Now what they’re looking at is the next step up, or the next phase. So, everything has gone through that clinical trials process. So, everyone should feel safe.”

One of the main benefits of participating in a clinical trial is being able to potentially access a new and better treatment. However, there are many other benefits according to Ms Young.

“It’s knowing that you’re part of a team, and knowing you are being monitored so closely and very regularly.”

“One of the fears that people diagnosed with cancer have is ‘how do I know that it hasn’t come back’,” she said.

“There is a real comfort in knowing that experts are keeping an eye on you and asking you questions and if people make a mention of a side effect, it triggers them to look at something. So, they’re being really closely monitored all the time.”

“I wasn’t on a trial when I received treatment a very long time ago, but I received the benefit of women who’d been on clinical trials before me and you know that your contributing to the future and to our daughters, and granddaughters and future women and men.”

Ms Young recommends anyone given the opportunity to participate in a clinical trial should consider it.

“You are monitored really carefully and you’re safe, and you have a chance of having access to the new drug that’s gone through scrutiny before humans are allowed to be trialled, maybe a step ahead of everybody else who has to wait maybe five or 10 years or more to get the treatment available.”

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Leonie Young

Former Chair of the Breast Cancer Trials Consumer Advisory Panel

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

IMMUNOTHERAPY AND THE PANACEA CLINICAL TRIAL

Immunotherapy allows cancer to become more visible to the immune system so the immune system can then attack it. The PANACEA clinical trial was Breast Cancer Trials first immunotherapy trial, and it has lead to further clinical trials research into this area of treatment.

Immunotherapy – An Emerging Treatment

The number of clinical trials using immunotherapy is increasing.

Immunotherapy drugs allow the cancer to become visible to the immune system, so the immune system can attack it. It has shown incredible success in melanoma, lung and bladder cancer, which previously had limited options for treatment.

Breast Cancer Trials currently has two open immunotherapy clinical trials, CHARIOT and DIAmOND.

However, before this came PANACEA.

The PANACEA Clinical Trial

PANACEA was Breast Cancer Trials first immunotherapy clinical trial, which paved the way for trials like DIAmOND.

Led by Professor Sherene Loi, PANACEA was studying women who had HER2-positive advanced breast cancer who had already received standard therapy such as trastuzumab or Herceptin based therapy, possibly alongside chemotherapy.

Professor Prue Francis is a medical oncologist and Chair of the Breast Cancer Trials Scientific Advisory Committee. She said PANACEA was exciting, as it was venturing into a new area of breast cancer research.

“The PANACEA trial was going into a new area for HER2 positive in breast cancer. It was looking at trying to introduce new immunotherapy into the treatment for women with HER2 positive breast cancer.”

It studied the most suitable dose of pembrolizumab and trastuzumab when these drugs are used together and to assess if their combined use is an effective treatment and can be used without chemotherapy.

“What was very exciting was there was some evidence of activity for this combination and so there will be future studies with immunotherapy as a result of this.”

“One of the things from the PANACEA trial that was learned was that the women who, when they studied their tumour and they found that their tumour had some expression of this marker called PDL1 or if they had a tumour infiltrating lymphocyte which are immune cells, that these were the women that potentially could benefit from that strategy.”

Listen to the podcast

Professor Prue Francis discusses the PANACEA clinical trial.

The DIAmOND and CHARIOT Clinical Trials

Two of these future immunotherapy studies are the Breast Cancer Trials clinical trials; DIAmOND and CHARIOT.

The PANACEA study led to the DIAmOND clinical trial.

“In the DIAmOND trial we’re studying women with HER2 positive advanced breast cancer and combining two immunotherapy drugs with the trastuzumab.”

“We’ll also be looking at women slightly earlier in the course of their advanced disease when they haven’t had quite so many therapies, because we think the immune system actually may be more receptive to these immune type treatments earlier in the course of the disease rather than waiting until there are no other therapies left.”

Professor Francis said although she is excited about the future of immunotherapy treatments, they still need to find what disease types will benefit most.

“I think it will become an important part of breast cancer, but I think that we will need to learn exactly which patients will be the ones who might benefit from immunotherapy.”

“At the moment the clues that we have is that there may be some patients with triple negative breast cancer that could benefit. So, that’s where there’s no oestrogen receptor, no progesterone receptor, no HER2 over expression” she said.

“Also, some with HER2 positive breast cancer.”

“At the moment for the most common type of breast cancer, which is oestrogen receptor positive, HER2 negative, it’s less clear what role immunotherapy will play because hormone therapy has been a very important treatment for that group.”

“But I think even amongst that group there will be women who could benefit from immunotherapy.”

“I think it’s a very exciting time at the moment in the immunotherapy field, to try and learn which women can benefit and how and in what context.”

profile image

Professor Prue Francis

Professor Prue Francis is a Breast Cancer Trials researcher and Clinical Head of Breast Medical Oncology at the Peter MacCallum Cancer Centre

YOU CAN HELP UNCOVER MORE EFFECTIVE TREATMENTS

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

YOUNG WOMEN & BREAST CANCER

Being diagnosed with breast cancer as a young women comes with its own set of unique challenges. The disease can have different characteristics in young women and have poorer survival outcomes when compared to older women.

Breast Cancer In Young Women

Being diagnosed with breast cancer as a young women comes with its own set of unique challenges.

The disease can have different characteristics in young women and have poorer survival outcomes when compared to older women.

Medical Oncologist and Chair of the Breast Cancer Trials Scientific Advisory Committee, Associate Professor Prue Francis said although it is more uncommon, breast cancer still occurs in younger women.

“About a quarter of women with breast cancer might be pre-menopausal or under the age of 50” she said.

“In breast cancer literature, very young women are often considered under the age of 35 and that’s less common.”

Around 800 young women will be diagnosed with breast cancer each year in Australia.

How Outcomes Can Differ In Young Women

Associate Professor Francis said although it is a smaller percentage, a diagnosis at a young age can have different implications than if you receive a diagnosis at a later stage in life.

“That’s the time of life when they might be building their career, building their family, building relationships and to be affected by breast cancer at that time is clearly devastating and plus we know that’s a group in which the cure rate has not been as high as in older women with breast cancer.”

She said the biology of the tumour could be to blame for these poorer outcomes.

“So, younger women are known on average to have more aggressive tumors biologically. These can be, in some instances, fast growing.”

Being Breast Aware

Younger women are typically diagnosed with more aggressive breast cancers and are at a higher risk of the disease spreading to other parts of the body.

Therefore, being aware of the normal look and feel of your breasts is just as important for young women as it is for older women according to Associate Professor Francis.

“Sometimes there is the perception that somebody might be too young to have breast cancer.”

“So, a women who’s in her early 20s might go to her GP with a breast lump and everybody might think ‘well she’s in her early 20s and she can’t have breast cancer’, and certainly that would be uncommon to have breast cancer at that age, but it can occur even in that age group” she said.

Listen to the podcast

Medical Oncologist Professor Prue Francis discusses breast cancer in young women on the Breast Cancer Trials podcast.

Treatments For Young Women

As younger women are often diagnosed with more aggressive breast cancers, the treatments can be more intense and aggressive. There are also a number of medical and pyscho-social challenges that some young women are faced with being diagnosed at an early stage of their life said Associate Professor Francis.

“Fertility is a big one because nowadays, particularly in western countries, as childbearing is often occurring later than it did in earlier decades. So, someone may be diagnosed with breast cancer in their thirties before they’ve commenced their child bearing. So, there’s all those issues about how to best protect their future fertility so that when the time is right, they can have the option for childbearing.”

She said surgery options also cause a lot of anxiety for young women.

“Sometimes when women are diagnosed with breast cancer at a young age, they’re so afraid of recurrence, that they feel like they just want to have all their breast tissue removed which is obviously a very big procedure for somebody at a young age.”

The cause of a young women’s breast cancer may also be investigated further.

“Genetic aspects come into it, because if somebody is diagnosed with breast cancer at a young age then it would be standard to consider whether there’s a genetic aspect” she said.

Research Into Treatments For Young Women With Breast Cancer

Breast Cancer Trials is committed to finding new and better treatments for young women with breast cancer.

Past Breast Cancer Trials clinical trials, the SOFT and TEXT clinical trials, helped to improve the treatment and survival for pre-menopausal women with oestrogen receptor positive or hormone receptor positive early breast cancer.

Previously, the hormone treatment given to these women post-surgery, and if required, after chemotherapy, was five years of tamoxifen.

Previous studies have shown that this treatment was not as effective for young women under 35, as compared to older pre-menopausal women.

“In trying to think about why that was we were thinking about oestrogen, which comes from the ovaries in pre-menopausal women” said Associate Professor Francis.

“When pre-menopausal, you have oestrogen produced from your ovaries every month and we noticed from previous trials when women were pre-menopausal and given adjuvant chemotherapy that the very young women were less likely to have their periods stop after they got chemotherapy compared to the older pre-menopausal women.”

“So, the closer you are to the natural age of menopause the more likely you are to go into menopause with chemotherapy, that might be temporary, or it might be permanent” she said.

“So if you’re 48, when you get chemotherapy your periods will probably stop, whereas if your 28 your periods are very unlikely to stop and so we wondered if the adverse outcomes in the younger women were the fact they were not getting this effect of their periods stopping and that their ovaries were continuing to produce oestrogen every month and perhaps that oestrogen could be effecting the growth of any remaining cancer cells.”

Associate Professor Francis said the most recent follow-up of the study has show there is an improvement in survival for women by suppressing the ovarian oestrogen for five years to tamoxifen.

“We feel that this treatment is going to be most beneficial in very young women or women with more high-risk features to their cancer. For example, several lymph nodes involved, more aggressive tumors.”

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Professor Prue Francis

Professor Prue Francis is a Breast Cancer Trials researcher and Clinical Head of Breast Medical Oncology at the Peter MacCallum Cancer Centre

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

THE SYMPTOMS OF BREAST CANCER BESIDES A LUMP

The most well-known symptom associated with breast cancer is finding a lump in the breast area. However, there are a number of physical signs or symptoms that could potentially indicate breast cancer.

What Are The Symptoms Of Breast Cancer Besides A Lump?

The most well-known symptom associated with breast cancer is finding a lump in the breast area. However, there are a number of physical signs or symptoms that could potentially indicate breast cancer. It is therefore important to be aware of the regular shape and feel of your breasts throughout the month and be aware of how your menstrual cycle can affects this. Pregnancy, weight and age can also alter the shape, feel and size of your breasts.

If you find one of the following symptoms, it’s important not to panic. Nine out of ten breast changes aren’t due to cancer. However, you should consult your doctor if you find any changes in your breasts.

It is also important to note that some breast cancers will not cause any symptoms at all. It is therefore important to get regular screening mammograms. BreastScreen Australia recommends women aged 50-74 without breast cancer symptoms should have a screening mammograms every two years. In New Zealand, women aged between 45 and 69 years are able to receive a free mammogram every two years.

Changes to Skin

Most changes to the skin of the breast are due to benign conditions, like allergies. However, changes in the look and feel of the skin of the breast, such as persistent skin redness, a rash, a scaly appearance, puckering, unusual redness or other colour changes, or dimpling (an ‘orange peel’ appearance) should be investigated further.

Changes to Breast Size and Shape

It’s quite common for your breasts to change due to hormone changes. Pregnancy can cause the breasts to increase by an average of two cup sizes, and your monthly period can also cause your breasts to change including feeling swollen, tender or lumpy before a period begins.

It’s important you are familiar with these changes. Most changes to the breast shape and size are not cancerous, however if you are concerned or have additional symptoms, speak with your doctor.

Changes to the Nipple

If there is a new change in the shape or look of your nipple, this could be a symptom of breast cancer.

A cancer may be present if there is nipple inversion – that is, the nipple is pulled in and cannot be pulled out to a normal shape, and rather than forming a slit shape the nipple is pulled in together, the nipple has any scaliness or crusting; an ulcer of sore; or unusual redness or a lump can be felt behind the nipple. However, nipple inversion may also occur naturally with increasing age.

Other physical signs or symptoms that could potentially indicate breast cancer can include pain in the armpit or breast, and nipple discharge. Find out more below.

breast cancer symptoms

  • Pain In Armpit and Breast (Breast Tenderness or Pain)

    Breast pain is not a common symptom of breast cancer. However, if the pain is new and persistent speak with you doctor.

    Most women will experience some sort of breast pain over the course of their life. Breast pain may be accompanied by tenderness, lumpiness, fullness, heaviness or an increase in breast size. The pain can also extend to the armpit.

    Breast pain can occur around the menstrual cycle, increasing around 3-7 days before the period begins. It is therefore important to be aware of how your menstrual cycle affects your breasts. Women can also experience breast pain when taking hormone replacement therapy after menopause.

    Other common reasons for breast and armpit pain can include stress, wearing an unsupportive bra, weight gain, injury to the breast and breast cysts or fibroadenomas.

    If you are concerned about breast pain, speak with your doctor.

  • Clear and Bloody Nipple Discharge

    Most nipple discharges will not be an indicator of breast cancer. However, a cancer may be present if the nipple discharge comes out without the nipple or breast being squeezed, comes from a single duct in one nipple, is blood-strained or tests positive for blood and is new, or in a woman 60 years or older.

Male Breast Cancer

For men, the most common symptom of breast cancer is a painless lump in the breast, often behind the nipple. The symptoms of male breast cancer closely resemble that of female breast cancer. If you notice a new change in your chest or nipples, talk to your doctor. If you are concerned about a change in your breasts, speak to your GP.

Breast Cancer Trials is a unique collaboration of researchers, trial participants and YOU, our valued supporters working together to save and improve the lives of every person affected by breast cancer. Help find the newest breakthrough in breast cancer research.

HELP FIND THE NEWEST BREAKTHROUGH IN BREAST CANCER RESEARCH

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

BREAST CANCER PREVENTION

Currently, there is no way to definitively prevent breast cancer from occurring. However, there are ways to manage some breast cancer risk factors to reduce the likelihood of future breast cancer.

How to Reduce Your Breast Cancer Risk

Over the course of your lifetime there are a number of risk factors you may be exposed to. Some cannot be changed, such as being a woman or having a strong family history, however other factors can be changed through healthy lifestyle decisions and risk-reducing strategies.

By better understanding your personal risk of breast cancer and getting regular screening, you can help improve your chance of better outcomes. You can use the iPrevent online tool to help better understand your breast cancer risk.

Clinical Trials Focused on Breast Cancer Prevention

A prevention-based breast cancer clinical trial is a research study designed to evaluate strategies, interventions, or treatments aimed at reducing the risk of developing breast cancer, particularly in individuals identified as having an increased risk. Breast Cancer Trials has conducted many clinical trials in the prevention setting including the BRCA-P clinical trial and IBIS-II clinical trial. Learn more about our successful trials and research. Donate to life-saving breast cancer clinical trials research.

How Can I Reduce My Risk Of Breast Cancer?

  • Diet

    There is no one single diet, food or supplement that can prevent or lower your risk of breast cancer. However, a healthy diet is still important to prevent against disease. Researchers have found that weight gain in middle life increases breast cancer risk.

  • Exercise

    Women can decrease their risk of breast cancer by engaging in regular exercise. Research has shown that in postmenopausal women, exercise and physical activity decreases the risk for breast cancer by changing oestrogen, insulin and insulin-like growth factor 1.

    Exercise can also positively affect other risk factors such as obesity and insulin resistance. It has also been shown that post-diagnosis physical activity in women with breast cancer can improve the survival chance of the patients. Ideally, exercise at least 30 minutes per day, 5 days per week at a moderate to high intensity.

  • Weight Control

    Obesity is associated with a 20% to 40% increased risk of breast cancer in post-menopausal women. In patients diagnosed with breast cancer, obesity is associated with a 33% increased risk of cancer recurrence and of death from any cause.

    Additionally, gaining weight as an adult is associated with an increased risk of post-menopausal breast cancer. The risk increases by about 6% for each 5 kg increase in a woman’s weight.

    However, having a higher BMI before menopause is associated with a decreased risk of premenopausal breast cancer. For each 5-unit increase in BMI, the risk of premenopausal breast cancer is decreased by about 7%. Importantly, obesity throughout life increases the risk of many other diseases such as heart disease and other cancers, leading to a higher rate of premature death.

  • Family History Awareness

    It’s important to be aware of your family history with breast cancer, as a person’s risk of being diagnosed with breast cancer increases if they have a close relative who has had breast cancer. It’s estimated that 4% of Australian women have an increased risk of breast cancer due to family history, and only 1% are at high risk due to a strong family history.

    Approximately 5-10% of breast cancers are due to a strong family history of genetic mutation such as BRCA1 or BRCA2. Some women with strong family histories receive genetic testing for breast cancer to see if they have one of these mutations.

  • Alcohol

    Globally, alcohol is identified as a risk factor for a range of soft tissue cancers, including breast cancer [6]. It’s estimated that approximately 17 per cent of Australians drink alcohol at levels that put them at risk of harm over their lifetime. Alcohol is the most-established dietary risk factor, thought to be due to the increase of endogenous oestrogen levels it causes.

    Women who drink one standard glass of alcohol (10g) a day have a 7 per cent higher risk of breast cancer than women who never drink alcohol. In Australia, it is estimated than almost 6 per cent of breast cancer cases each year are caused by alcohol consumption.

    Evidence suggests there is no safe level of alcohol consumption in regard to an increased breast cancer risk, with a meta-analysis of 222 articles finding even light drinking (up to one drink per day) increases the risk of female breast cancer.

  • Smoking

    Several studies have shown there is an association between tobacco smoking and the risk of breast cancer. This association is observed particularly in women who smoke for a long time, or who smoke for a long time prior to their first pregnancy.

    Tobacco smoke contains more than 5000 chemical compounds, including more than 70 that are known to be carcinogenic. Smoking has been found to be a major cause of heart disease, lung cancer and many other cancers, therefore not smoking is the best choice for your health.

  • Medication

    Tamoxifen, a medication that is commonly used to treat breast cancer, also helps prevent breast cancer from occurring. It may be considered for women who are at a high risk of breast cancer due to their personal or family history.

The Importance of Breast Cancer Screening

The earlier breast cancer is found, the better the chance of survival. Screening mammography can detect breast cancer at its earliest state, before it can be felt.

BreastScreen Australia recommends women aged 50-74 without breast cancer symptoms should have a screening mammograms every two years. This is the targeted age group as more than 75% of breast cancers occur in women aged over 50. Women aged 40-49 and 75 and over are eligible to receive free mammograms but do not receive an invitation to attend.

In New Zealand, women aged between 45 and 69 years are able to receive a free mammogram every two years.

Ways to Prevent Breast Cancer

Medical Interventions

There are several medical interventions available to help prevent breast cancer, particularly for individuals at higher risk due to genetic factors, family history, or other risk factors. These interventions include medications, surgeries, and other medical strategies based on an individual’s risk profile.

  • Risk-reducing medications: Certain medications can help lower the risk of developing breast cancer, especially those that are hormone-receptor positive. These can include tamoxifen, anastrozole, and exemestane.

Surgical Options

For individuals with a very high risk (e.g., BRCA1/BRCA2 mutation carriers), surgery can dramatically reduce the risk of breast cancer.

  • Prophylactic (Preventive) Mastectomy: Involves the surgical removal of one or both breasts before cancer develops. Reduces breast cancer risk by up to 95% in high-risk individuals.

Removing Ovaries to Prevent Breast Cancer

A Prophylactic Oophorectomy is the removal of the ovaries and fallopian tubes to lower estrogen levels, reducing the risk of both breast and ovarian cancers. This is often recommended for women with genetic mutations like BRCA1/2, especially after childbearing.

Benefits of Oopherectomy:

  • Reduced Cancer Risk: For premenopausal women, oophorectomy lowers estrogen levels, reducing the risk of hormone-receptor-positive breast cancer by up to 50%. In relation to ovarian cancer, reduces the risk by up to 95% in high-risk individuals (e.g., BRCA mutation carriers).
  • Improved Survival: Studies suggest that prophylactic oophorectomy can significantly increase life expectancy for women with genetic predispositions to breast or ovarian cancer.
  • Simplicity of Proceedure: An oopherectomy is a relatively straightforward surgical procedure, often performed laparoscopically (minimally invasive), with a shorter recovery time than more extensive surgeries.
  • Eliminated Future Ovarian Issues: Prevents benign (non-cancerous) ovarian conditions, such as ovarian cysts or endometriosis, which can require further treatment.

Risk Associated with Oopherectomy:

  • Surgical Risks: This can include typical risks of surgery such as bleeding, infection, and adverse reactions to anesthesia. Rare complications associated with surgical proceedures can include damage to nearby organs like the bladder or intestines.
  • Premature Menopause: Unfortinately for premenopausal women, oophorectomy causes immediate menopause. Symptoms include hot flashes, night sweats, vaginal dryness, mood swings, and sleep disturbances. This may increase the risk of osteoporosis, heart disease, and cognitive decline due to the loss of estrogen.
  • Impact on Fertility: Permanently ends the ability to conceive naturally, which can be a significant consideration for younger women.
  • Potential Psychological Impacts: Loss of fertility and the sudden onset of menopause can lead to feelings of grief, anxiety, or depression. Some women may experience a reduced sense of femininity or sexual confidence.
  • Residual Cancer Risk: Oophorectomy does not eliminate all cancer risk. There’s still a slight chance of developing primary peritoneal cancer (a rare cancer that arises in the lining of the abdomen, which shares origins with ovarian tissue).

Removing Breast Tissue to Prevent Breast Cancer

A prophylactic mastectomy is the surgical removal of one or both breasts in individuals who do not have breast cancer but are at high risk of developing it. This preventive procedure is intended to significantly reduce the risk of breast cancer, especially in those with genetic predispositions or other high-risk factors.

This procedure is typically recommended for individuals at high risk of breast cancer, including:

Genetic Risk:

  • BRCA1/BRCA2 Mutations: Women with these mutations have up to a 72% lifetime risk of breast cancer.
  • Other gene mutations like PALB2, TP53, and CHEK2.

Strong Family History:

  • Multiple close relatives (e.g., mother, sister, or daughter) diagnosed with breast or ovarian cancer, especially at a young age.

Personal Medical History:

  • Previous cancer in one breast (may opt for removal of the other breast to prevent future cancer).
  • History of atypical hyperplasia or lobular carcinoma in situ (LCIS), which are precancerous conditions.

Dense Breast Tissue:

  • Dense tissue can make cancer harder to detect with imaging and may slightly increase cancer risk.

The decision to undergo a prophylactic mastectomy is highly personal and depends on:

  • Your genetic risk profile.
  • Family and personal medical history.
  • Emotional readiness for the physical and psychological impact.
  • Long-term lifestyle and health goals.

Consult with a genetic counselor, oncologist, and plastic surgeon to fully understand the risks, benefits, and alternatives before making a decision. Other options, such as enhanced screening or chemoprevention, may also be worth exploring for risk management.

FAQs

Does Breastfeeding Prevent Breast Cancer?

Breastfeeding has been shown to lower the risk of breast cancer, particularly for hormone-receptor-positive types. The protective effect occurs for several reasons. First, breastfeeding lowers estrogen levels in the body during lactation. Since some types of breast cancer are fueled by estrogen, this reduced exposure to the hormone can help decrease the risk.

Additionally, breastfeeding causes the body to shed breast tissue, potentially removing cells with DNA damage that could otherwise develop into cancer. Breastfeeding also delays the return of menstruation, which reduces lifetime exposure to estrogen and progesterone, further lowering cancer risk. Moreover, the act of breastfeeding induces changes in breast cells that may make them more resistant to cancerous transformations.

The protective effect of breastfeeding increases with the duration of breastfeeding. Research suggests that breastfeeding for at least 12 months (across all children) may reduce breast cancer risk by 4–5% per year of breastfeeding. The longer the duration, the greater the benefit. Exclusive breastfeeding, where no formula feeding is involved, seems to enhance this protective effect even further.

Does Breast Massage Prevent Cancer?

Breast massage does not prevent breast cancer. While some people believe that regular breast massage can help with early detection by making it easier to feel lumps or changes in the breast tissue, there is no scientific evidence to support the idea that breast massage itself can prevent the development of cancer.

Breast cancer is a complex disease influenced by factors such as genetics, hormones, age, and lifestyle choices. While maintaining regular self-exams is an important part of breast health, it is the early detection of changes—such as lumps, thickening, or skin changes—that matters most for finding cancer at an early stage. However, breast massage is not a substitute for regular screenings, such as mammograms or clinical breast exams, which are proven to be more effective in detecting breast cancer.

Do Breast Implants Prevent Breast Cancer?

Breast implants do not prevent breast cancer. In fact, they do not offer any protective benefits against the development of breast cancer. While breast implants may change the appearance of the breasts, they do not affect the underlying risk factors associated with breast cancer, such as genetics, age, or lifestyle.

However, it is important to note that breast implants can make it more challenging to detect breast cancer through routine screening methods like mammograms. The implants can obscure breast tissue, potentially hiding tumors or making it more difficult for radiologists to interpret results accurately. Special imaging techniques, such as additional views during mammography or breast MRI, are sometimes used to help get clearer images for women with implants.

While breast implants themselves do not prevent cancer, they are not directly linked to an increased risk of breast cancer either. There are, however, certain rare conditions associated with breast implants, such as anaplastic large cell lymphoma (ALCL), a type of cancer that can develop in the tissue surrounding the implant. This is not the same as breast cancer but is an important consideration for women with implants.

Does Breast Reduction Prevent Breast Cancer?

Breast reduction surgery does not prevent breast cancer, but it may reduce some of the risks associated with the disease. The procedure involves the removal of excess breast tissue to reduce breast size and alleviate discomfort, particularly for women with very large breasts. While this can improve physical and emotional well-being, it does not eliminate the risk factors for breast cancer, such as genetics, age, or lifestyle.

One indirect benefit of breast reduction is that it can make it easier for individuals to perform regular self-breast exams and undergo screenings like mammograms. With smaller breasts, there may be less tissue to examine, which could lead to a more accurate detection of any potential changes or lumps. However, breast reduction does not remove all of the breast tissue, so regular screenings and exams are still necessary.

There is also some evidence that breast reduction might slightly lower the risk of developing breast cancer by removing some of the breast tissue that could potentially develop into cancer. However, this effect is minimal, and breast cancer prevention still largely depends on factors like genetics, lifestyle choices, and routine screening practices.

How You Can Help

We want to ensure no more lives are cut short by breast cancer. Support our life changing research with a donation, or participate in a clinical trial to help us to find a cure.

YOU CAN HELP SAVE HER PLANS, HER DREAMS, AND HER LIFE

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

SOLACE – A CLINICAL TRIAL FOR BREAST AND OVARIAN CANCER

The SOLACE clinical trial was for women or men who had been diagnosed with advanced BRCA-associated breast cancer, triple negative breast cancer or serious ovarian cancer. Listen in to see how these results are informing current research into ovarian and breast cancer. Professor Prue Francis discusses the results from this trial and how the knowledge gained is being used in current research.

What Is The SOLACE Clinical Trial?

The Breast Cancer Trials SOLACE trial was a clinical trial for men and women with BRCA-associated breast cancer, triple negative breast cancer or serious ovarian cancer.

SOLACE was an important trial for the treatment of ovarian cancer, and the results and treatments from this trial are being further investigated in more recent breast cancer clinical trials like OlympiA.

Medical Oncologist Professor Prue Francis is the Chair of the Breast Cancer Trials Scientific Advisory Committee.

She said the aim of the trial was to determine the appropriate doses of a new combination drug treatment.

“It was trying to look at combining a drug called Olaparib, which is a PARP inhibitor, with a very common chemotherapy drug; Cyclophosphamide.”

“The SOLACE trial involved women having an all tablet therapy, Olaparib; the PARP inhibitor as tablets and the Cyclophosphamide as tablets, and it was studying a couple of different groups of women.”

Listen to the Podcast

Professor Prue Francis discusses the results from the SOLACE trial and how the knowledge gained is being used in current research.

A Trial For Breast And Ovarian Cancer

Professor Prue Francis it was important to include women with breast and ovarian cancers in the trial.

“The reason we included both breast and ovarian cancer was because PARP inhibitors like Olaparib are potentially active in women who have a genetic mutation called the BRCA-1 mutation or the BRCA-2 mutation and those mutations are associated potentially with both breast and ovarian cancer.”

“Women could participate in the trial if they had either breast cancer and had one of these gene mutations or if they had triple negative breast cancer- so that’s a breast cancer that doesn’t express oestrogen or progesterone receptor and doesn’t over express HER2.”

“In ovarian cancer, there were women who had high grade serious ovarian cancer or who had one of these BRCA mutations in association with their ovarian cancers.”

Associate Professor Francis said the trial allowed people to participate who had already received a number prior therapies for their advanced disease and for breast cancer.

“The trial approach didn’t look particularly promising for the future in that setting, and so perhaps if we were looking at that approach in breast cancer with a PARP inhibitor, we’d be needing to think about it earlier in the therapy stage.”

“For example, since we’ve started conducting the SOLACE trial, Olaparib the PARP inhibitor, has been approved in Australia for women with earlier breast cancer, as in advanced breast cancer but in an earlier therapy setting, because there if some efficacy there.”

Further Research On Olaparib – OlympiA

Since the SOLACE trial, Breast Cancer Trials has continued to study Olaparib in the OlympiA trial, for women who have completed their surgery and other local therapies.

The OlympiA study is open to those with HER2 negative breast cancer who also have inherited BRCA1 and BRCA2 mutations.

“So, the drug itself is still being actively studied in breast cancer, but in the actual SOLACE trial for the women who’d had quite a few different therapies for their advanced breast cancer, we did not see long periods of control in that context” said Associate Professor Francis.

However, SOLACE has provided further opportunities for study for those with ovarian cancer.

“The gynaecology oncologists are actually interested in the results of SOLACE because for the women with ovarian cancer and particularly those who had the BRCA mutations, they did get reasonable periods of tumour control with that combination” said Associate Professor Prue Francis.

“It is an interesting combination for them to go and study further in that particular setting.”

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Professor Prue Francis

Breast Cancer Trials Researcher and Clinical Head of Breast Medical Oncology at the Peter MacCallum Cancer Centre.

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

DENSE BREASTS

Dense breasts are more common in young woman and women with dense breasts can be five times more likely to develop breast cancer.

What Are Dense Breasts & How Do I Know If I Have Them?

Do you know if your breasts are dense?

Dense breasts are more common in young woman and women with dense breasts can be five times more likely to develop breast cancer.

However, it is not something that is commonly discussed between doctor and patient.

Rik Thompson is the Associate Director and a Professor of Breast Cancer Research at the Institute of Health and Biomedical Innovation and School of Biomedical Science at Queensland’s University of Technology. He is also a Breast Cancer Trials Board Member.

A research focus for Professor Thompson is mammographic density or dense breasts.

What Is Mammographic Density?

“Mammographic density is the whiteness on your mammogram” said Professor Thompson.

“Without having a cancer in it, the normal breast mammogram can either be quite dark or will have different amounts of whiteness in it and it’s the whiteness which is the mammographic density.”

Professor Thompson said its not possible to know if you have dense breasts by feel or touch alone.

“It’s not dense to touch, it’s not a lump, it’s not firm but it blocks x-rays.”

Listen to the podcast

Dense breasts are more common in young woman and women with dense breasts can be five times more likely to develop breast cancer.

Research Into Mammographic Density (Dense Breasts)

Research into mammographic density is incredibly important as your risk of breast cancer is higher if you have dense breasts, but researchers are not yet sure why.

“It’s linked with oestrogen action which is known to be a promoter for breast cancer” said Professor Thompson.

“It’s got some genetic links. So, some of the genes which are linked to mammographic density are the same as those that have an effect on breast cancer predisposition and risk, but a lot of them are not.”

“We’re trying to find out at a molecular level why are the cells in those dense regions, or in denser breasts, are more likely to end up becoming a breast cancer.”

How Common Are Dense Breasts?

Around 45% of women have dense breasts according to Professor Thompson. However, as Australia does not have a notification process surrounding mammographic density, many woman are unaware of it.

“It’s something that’s being hotly debated and investigated and considered in Australia.”

“There’s quite a number of approaches and workshops and special initiatives to try and understand how best to deal with this information, how to accommodate it, how to afford it, how to pass it on in a meaningful way.”

What Do I Do If I Have Dense Breasts?

If women are concerned about mammographic density, they could take a look at their mammogram and discuss mammographic density with their GP said Professor Thompson.

“I think most women could look at the literature and look at the websites around mammographic density and have a look at their mammogram and they could get a pretty good picture as to whether they’re dense or not.”

“It’s certainly something that I think increasingly women could discuss with their GP.”

If you are aware of your mammographic density, Professor Thompson stresses that you should still get regular screening.

“I think the most important thing even if mammograms don’t work as well in dense breasts because it can mask it, mammography is still the best way to find breast cancers, even in the densest scenario.”

“Women shouldn’t ever think ‘I won’t get a mammogram anymore, it doesn’t help me, my breasts are too dense’. You can still find breast cancers and it’s very clear from all the professional groups that it’s paramount.”

He also said that having dense breasts is no cause for alarm.

“Mammographic Density is only one of a number of risk factors for breast cancer.”

“You could have the densest breasts in the world but if you had no other risk factors, you’re probably still fine.”

“So, you’ve got to look at your family history, you’ve got to look at your age, your BMI, and all of those factors that are well established and so, it’s really a composite assessment of risk that probably should be what’s used to think about what to do next.”

If you would like to learn more about mammographic density, you can visit www.informd.org.au

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Professor Rik Thompson

Professor Rik Thompson is the Associate Director and a Professor of Breast Cancer Research at the Institute of Health and Biomedical Innovation and School of Biomedical Science at Queensland’s University of Technology.

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer

WHAT’S IT LIKE TO PARTICIPATE IN A CLINICAL TRIAL?

More than 15,000 women have participated in Breast Cancer Trials clinical trials. One of those women is Leslie Gilham, who was a participant in the TEXT clinical trial, a practice changing study for the treatment of young women with breast cancer.

The Importance Of Clinical Trials

In the past 20 years, the chance of surviving five years after a breast cancer diagnosis in Australia has increased from 73% to 91%.

It is thanks to the incredible advances in breast cancer research that we have seen these improvements in survival rates.

But without clinical trial participants these advances could not have been possible.

More than 15,000 women have participated in more than 80 Breast Cancer Trials clinical trials.

One of those women is Leslie Gilham, who was a participant in the TEXT clinical trial.

The TEXT Clinical Trial

TEXT was a practice changing study into the treatment of breast cancer in young women.

It showed that the aromatase inhibitor, exemestane, is more effective than tamoxifen in preventing breast cancer coming back in young women who also receive ovarian function suppression.

However, Leslie said she had not heard of clinical trials until her first meeting with her oncologist.

“We went through my treatment plan and he raised the possibility of there being a clinical trial that I might be suitable for and would I be interested?”

“So, I took away all the information for the trial and had time to consider it and weigh up whether I wanted to participate, and I did.”

TEXT was a randomised trial, with half the participants receiving Tamoxifen and half an aromatase inhibitor.

It also involved having triptorelin to suppress the patient’s ovaries and put them through menopause.
Leslie said she felt she was well-informed about the trial before signing on.

“I had a meeting with my oncologist who suggested the trial and he brought in the research nurse.”

“So, they basically went through the whole protocol for the trial with me and discussed it in detail and probably for around about an hour” she said.

“Then I was given the protocol and the informed consent to take home and consider and so I could go home and discuss it with my family, whether to participate or not, and then basically made the decision and came back agreed to participate. “

Listen to the podcast

More than 15,000 women have participated in Breast Cancer Trials clinical trials. One of those women is Leslie Gilham, who was a participant in the TEXT clinical trial, a practice changing study for the treatment of young women with breast cancer.

The Benefits Of Participating In A Clinical Trial

Leslie said she felt fully supported throughout the duration of her trial.

“Part of the trial was that you had to attend the clinic more often than the average patient.”

“I was also constantly receiving phone calls from the research team and I also had to fill out quality of life studies, so you’re sort of more aware of where you are at, and I guess the treatment itself.”

“I mean statistics show that people on trials do better than people off trial and I think that’s basically because you get more support from the team while you’re on trial.”

Leslie said although the support was an added bonus, her reasons for participating in a clinical trial was closer to her heart.

“I had a friend who was diagnosed five years prior to me and one the drugs, if she was diagnosed at the same time as me, she would have had access to.”

“But she didn’t have access to it, and I’m pretty sure she would not have passed away if she had access to that drug” said Leslie.

“So, I guess it brought it home to me, the importance of the treatments improving all the time and the survival rates improving as a result of that. So, I guess that and the combination of having a daughter.”

“I was very keen on playing my part to improving treatments and overall survival rates.”

Leslie said she is proud her participation in a clinical trial has helped inform practice for how breast cancer is treated in Australia and New Zealand.

“It was because of the (trial) data that was collected that they said it would now be the standard treatment or gold-standard treatment for my type of breast cancer.”

“I was a little bit proud because I thought, well it was worth participating and it was worth putting my hand up and hopefully making a difference to the future generations.”

Leslie recommends participating in a clinical trial to anyone who is provided the opportunity.

“When you’ve got a diagnosis, and you’ve got so many things going on in your head at the time, it’s good to be able to focus on something and I found that was a really good way of being able to get through my treatments.”

“But also, it’s that ability to hopefully make a difference.”

“The other thing that I found really important and really fulfilling was I felt like I was part of a team, being the research team.”

“They included me in every decision process. I always remember, other than the day I was diagnosed, the hardest day was saying goodbye to my research team after five years.”

Leslie Gilham is a past clinical trial participant and the current chair of the Breast Cancer Trials Consumer Advisory Panel.

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Leslie Gilham

Leslie Gilham is the Chair of the Breast Cancer Trials Consumer Advisory Panel

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

UNDERSTANDING BREAST CANCER STATISTICS & SURVIVAL RATES

Collating breast cancer statistics is important in order to track how many people are being diagnosed with and surviving breast cancer each year. These statistics allows us to track how improved treatments and screening techniques have contributed to better survival rates.

Why Are Breast Cancer Statistics & Survival Rates Important?

Collating breast cancer statistics is important in order to track how many people are being diagnosed with and surviving breast cancer each year. These statistics allows us to track how improved treatments and screening techniques have contributed to better survival rates.

It is also important to record how different factors can vary these statistics. For example: types of cancer, stage of cancer, age and gender.

This information allows doctors to better inform their patients of their individualised survival chances, which can also help to inform treatments.

New Cases of Breast Cancer

In 2019, the Australian Institute of Health and Welfare predicts 19,371 women and 164 men in Australia will receive a breast cancer diagnosis. In New Zealand, approximately 3,500 people will be diagnosed with breast cancer. It is the most commonly diagnosed cancer for Australian and New Zealand women.

The number of people diagnosed with breast cancer has steadily increased over time, however survival rates have improved. In the past 20 years, the five-year relative survival rate for early stage breast cancer has increased from 73% to 91% in Australia. In New Zealand, the chance of surviving five years is 88%. The chance of surviving at least ten years in Australia is 83%, while in New Zealand it is 80-95%, if detected early via a mammogram.

Survival Statistics By Stage of Diagnosis

The relative five-year survival rate for a female diagnosed with breast cancer in its earliest stage or stage one is effectively 100%, according to 2011 data from the Australian Institute of Health and Welfare. When females are diagnosed with metastatic breast cancer (advanced or stage four), the 5-year survival rate is reduced to 32%1. This highlights the important of detecting cancer at an earlier stage to improve survival chances.

On average, breast cancer in females is diagnosed at stage one or two. The higher proportion of cases diagnosed as stage one and two for breast cancer may be partly attributable to the national breast cancer screening program.

Breast Cancer Mortality Rates

In 2019, the Australian Institute of Health and Welfare estimates 3,090 people will die from breast cancer. It is the 4th leading cause of death from cancer in Australia. The risk of dying from breast cancer before age 75 is 1 in 78 for women, and 1 in 7,922 in males. The risk of dying from breast cancer before age 85 is 1 in 43 for women and 1 in 3,455 for males.

In New Zealand, approximately 630 people will die from breast cancer this year. About 70% of women who are diagnosed with breast cancer and about 80% of women who die from it are 50 years or older.

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer
split-banner-image

COMMON BREAST CANCER
MYTHS AND FACTS

There are a lot of myths regarding breast cancer and this can make it difficult to separate fact from fiction. Here are just some of the common breast cancer myths explained:

Common Breast Cancer Myths And Facts

There are a lot of myths regarding breast cancer and this can make it difficult to separate fact from fiction. Here are just some of the common breast cancer myths explained:

  • Myth: Only Women Get Breast Cancer

    Although it is less common, men can get breast cancer. Male breast cancer accounts for less than 1% of all breast cancers diagnosed.

    Approximately, 164 men will be diagnosed with breast cancer in Australia this year and around 25 men in New Zealand. Treatment for both men and women diagnosed with breast cancer are very similar.

  • Myth: Wearing An Underwire Bra Can Cause Breast Cancer

    Every so often this myth will gain traction on the internet, but there is no credible evidence to back it up.

    A 2005 population-based case-control study of around 1,500 women diagnosed with two of the most common histological types of breast cancer, invasive ductal carcinoma cases (IDC) and invasive lobular carcinoma (ILC) and a control group of women, found no aspect of bra wearing, including bra cup size, average number of hours/day worn, wearing a bra with an underwire or age when first began regularly wearing a bra, was associated with risks of any of the most common types of breast cancer.

    The myth about a link between wearing an underwire bra and breast cancer comes from concern about bras impeding lymphatic drainage, interfering with toxin removal. Another theory without any factual basis is that bras cause cancer by increasing the surface temperature of the breast.

    To be clear, there are NO credible scientific studies or any other evidence of any association between any aspect of wearing a bra and breast cancer risk.

  • Myth: Breast Implants Increase The Risk Of Breast Cancer

    Several studies have been completed examining if there is a connection between silicone-filled breast implants and breast cancer.

    In these studies, there was no conclusive evidence found that women who have undergone cosmetic breast implantation have an increased risk of the most common types of breast cancer.

    However, there is an extremely rare condition associated with breast implants; breast implant associated anaplastic large cell lymphoma.

  • Myth: Contraceptive Pills Cause Breast Cancer

    Taking oral contraceptives or ‘the pill’ has been associated with a small increased risk of breast cancer while the woman is currently using it.

    The risk of being diagnosed with breast cancer for women using the ‘combined’ oral contraceptive pill increases by about 7% for every five years of use.

    However, this risk is reduced when the woman stops taking it.

  • Myth: All Breast Cancer Types Are Genetic

    A person’s risk of being diagnosed with breast cancer increases if they have a close relative who has had breast cancer – on either their mother’s or father’s side – particularly if they were diagnosed under the age of 50.

    However, most women who develop breast cancer have no family history of the disease. The majority of breast cancer diagnoses are not linked to an inherited gene.

    It is estimated that 95% of Australian women are of average risk, 4% have an increased risk of breast cancer due to family history, and only 1% are at high risk due to a strong family history.

    Of these 1%, only half have a known gene that is likely to have been inherited from their mother of father’s side. The other half may have an inherited gene that we do not yet have a test for.

    Genetic Risks for Developing Breast Cancer

    • Women with one first-degree relative (parent, sibling or child) who has had breast cancer have almost two times the risk of breast cancer compared to women with no family history.
    • Women with two first degree relatives who have received a breast cancer diagnosis, have almost three times the risk of developing breast cancer compared to women with no family history.
    • Women with three or more first-degree relatives are almost four times as likely to be diagnosed with breast cancer.
    • If a woman has one or more second degree relatives who have received a breast cancer diagnosis (aunt, uncle, grandparent, grandchild, niece, nephew or half-sibling) they are estimated to have one and a half times the risk of being diagnosed with breast cancer compared with someone who has no family history.

    As breast cancer is the most commonly diagnosed breast cancer in Australia, some women will have a family history of the disease by chance.

    However, some woman may have inherited a faulty or mutated gene, like BRCA1 or BRCA2, which increases the risk of cancer. Around 5-10% of breast cancers are due to an inherited gene like BRCA1 or BRCA2.

  • Myth: Deodorants and Antiperspirants May Cause Breast Cancer

    There is no evidence that deodorants or antiperspirants cause breast cancer. This myth was perpetuated by several poor-quality studies.

    These studies proposed a theoretical link between deodorants and antiperspirants containing chemicals such as parabens and aluminium compounds that are applied close to where breast cancer can develop.

    However, a high-quality systematic review of all available studies showed there is no reliable evidence to suggest that the use of deodorants or antiperspirants increases the risk of breast cancer.

  • Myth: All Lumps In The Breast Are Cancerous

    Most lumps in the breast are not cancerous. Most breast changes are likely to be normal or due to a benign breast condition. Some benign breast changes may need treatment, but this is not always the case.

    However, if you do notice a change in your breasts, you should discuss this with your GP to make sure that the changes are not something more serious.

    Changes to look out for include new lumps in the breast or under the arm, nipple inversion or discharge, skin thickening or swelling.

  • Myth: Fertility Treatments Can Cause Breast Cancer

    The is no clear or conclusive evidence that hormonal treatment for infertility can cause an increased risk of breast cancer.

    An analysis of 20 studies found hormonal infertility treatments are not associated with an increase BC risk.

    There was also no increased risk found in women undergoing IVF treatment.

HELP CHANGE HER STORY, SUPPORT BREAST CANCER RESEARCH

Latest Articles

bridging science and experience: the impact of the consumer advisory panel
improving efficacy in the adjuvant treatment of early er+ breast cancer